JP2025508739A5 - - Google Patents

Info

Publication number
JP2025508739A5
JP2025508739A5 JP2024548575A JP2024548575A JP2025508739A5 JP 2025508739 A5 JP2025508739 A5 JP 2025508739A5 JP 2024548575 A JP2024548575 A JP 2024548575A JP 2024548575 A JP2024548575 A JP 2024548575A JP 2025508739 A5 JP2025508739 A5 JP 2025508739A5
Authority
JP
Japan
Prior art keywords
cdr
amino acid
acid sequence
seq
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/062822 external-priority patent/WO2023159182A1/en
Publication of JP2025508739A publication Critical patent/JP2025508739A/ja
Publication of JP2025508739A5 publication Critical patent/JP2025508739A5/ja
Pending legal-status Critical Current

Links

JP2024548575A 2022-02-18 2023-02-17 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体分子、それをコードするポリヌクレオチド、および使用方法 Pending JP2025508739A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311924P 2022-02-18 2022-02-18
US63/311,924 2022-02-18
PCT/US2023/062822 WO2023159182A1 (en) 2022-02-18 2023-02-17 Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use

Publications (2)

Publication Number Publication Date
JP2025508739A JP2025508739A (ja) 2025-04-10
JP2025508739A5 true JP2025508739A5 (https=) 2026-02-19

Family

ID=85685785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548575A Pending JP2025508739A (ja) 2022-02-18 2023-02-17 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体分子、それをコードするポリヌクレオチド、および使用方法

Country Status (11)

Country Link
US (1) US20250145716A1 (https=)
EP (1) EP4479431A1 (https=)
JP (1) JP2025508739A (https=)
KR (1) KR20240158391A (https=)
CN (1) CN119095874A (https=)
AU (1) AU2023221861A1 (https=)
CA (1) CA3252736A1 (https=)
MA (1) MA67298A1 (https=)
MX (1) MX2024010003A (https=)
TW (1) TW202342520A (https=)
WO (1) WO2023159182A1 (https=)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JP5225069B2 (ja) 2005-03-23 2013-07-03 ゲンマブ エー／エス 多発性骨髄腫の治療のためのｃｄ３８に対する抗体
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
EP2361263A1 (en) 2008-10-31 2011-08-31 Abbott Biotherapeutics Corp. Use of anti-cs1 antibodies for treatment of rare lymphomas
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
CA3070469C (en) 2016-10-25 2022-06-21 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
CN115052631A (zh) * 2019-12-06 2022-09-13 乐天医药生技股份有限公司 用于增强免疫及肿瘤治疗的方法
WO2021207691A1 (en) 2020-04-10 2021-10-14 Rakuten Medical, Inc. Phthalocyanine dye compounds, conjugates and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7194762B2 (ja) 抗ｎｔｂ－ａ抗体及び関連組成物ならびに方法
US11584801B2 (en) Anti-5T4 antibodies and antibody-drug conjugates
AU2020200175B2 (en) Site-specific conjugation of linker drugs to antibodies and resulting ADCS
AU2009321252B2 (en) Antitumor combinations containing antibodies recognizing specifically CD38 and cylophosphamide
JP2020520370A5 (https=)
JP2024001187A (ja) 乳がんの処置のためのヒト化抗ｌｉｖ１抗体
JP7724866B2 (ja) 抗体薬物複合体およびその用途
JP2021523158A5 (https=)
JP2021523233A5 (https=)
JP2022521305A (ja) 抗ｐｄ－ｌ１抗体及びその使用
JP2023519807A5 (https=)
WO2023225577A1 (en) Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates
JP2025503229A (ja) 抗ｈｅｒ２／ｔｒｏｐ２抗体及びその使用
TW202306588A (zh) 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途
JP2025508739A5 (https=)
CN119584995A (zh) 组合疗法
CN119894929A (zh) 使用PD-1或PD-L1抑制剂和靶向Claudin 18.2的抗体药物偶联物的癌症治疗
AU2024298986C1 (en) Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof
EP4428158A1 (en) Lung cancer targeting human antibodies and therapeutic uses thereof
KR20250108097A (ko) Egfr을 표적으로 하는 항체-약물 접합체를 이용한 비인두암 치료
TW202423485A (zh) 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合
CA2947238C (en) Site-specific conjugation of linker drugs to antibodies and resulting adcs
HK40104915A (zh) 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法
RU2020143543A (ru) Биспецифические антитела против ceacam5 и cd47
EA044092B1 (ru) Анти-ntb-a антитела и терапевтические композиции, их содержащие